<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="8" ids="10033">Warfarin</z:chebi> increases both the likelihood and the mortality of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>), particularly in patients with a history of prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> </plain></SENT>
<SENT sid="1" pm="?"><plain>In light of this consideration, should a patient with both a history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and a clear indication for anticoagulation such as nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> be anticoagulated </plain></SENT>
<SENT sid="2" pm="."><plain>In the absence of data from a clinical trial, we used a decision-analysis model to compare the expected values of 2 treatment strategies-<z:chebi fb="8" ids="10033">warfarin</z:chebi> and no anticoagulation-for such patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used a Markov state transition decision model stratified by location of <z:mp ids='MP_0001914'>hemorrhage</z:mp> (lobar or deep hemispheric) </plain></SENT>
<SENT sid="4" pm="."><plain>Effectiveness was measured in quality-adjusted life years (QALYs) </plain></SENT>
<SENT sid="5" pm="."><plain>Data sources included English language literature identified through MEDLINE searches and bibliographies from selected articles, along with empirical data from our own institution </plain></SENT>
<SENT sid="6" pm="."><plain>The base case focused on a 69-year-old man with a history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and newly diagnosed nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: For patients with prior lobar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>, withholding anticoagulation therapy was strongly preferred, improving quality-adjusted life expectancy by 1.9 QALYs </plain></SENT>
<SENT sid="8" pm="."><plain>For patients with prior deep hemispheric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>, withholding anticoagulation resulted in a smaller gain of 0.3 QALYs </plain></SENT>
<SENT sid="9" pm="."><plain>In sensitivity analyses for patients with deep <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>, anticoagulation could be preferred if the risk of <z:hpo ids='HP_0001727'>thromboembolic stroke</z:hpo> is particularly high </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Survivors of lobar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> should not be offered long-term anticoagulation </plain></SENT>
<SENT sid="11" pm="."><plain>Similarly, most patients with deep hemispheric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> should not receive <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="12" pm="."><plain>However, patients with deep hemispheric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> at particularly high risk for <z:hpo ids='HP_0001727'>thromboembolic stroke</z:hpo> or low risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> recurrence might benefit from long-term anticoagulation </plain></SENT>
</text></document>